

---

**Optimized HF therapy in patients with very advanced cancer in palliative care: dosing strategies from the EMPATICC trial**

---

[10.4081/cardio.2025.78](https://doi.org/10.4081/cardio.2025.78)

**Declaration of Interest Report**

---

Markus S. Anker (MSA), Muhammad Shahzeb Khan (MSK), Amir A. Mahabadi (AAM), Matthias Totzeck (MT), Mitra Tewes (MTe), Muhammad Sameer Arshad (MSAr), Raluca Mincu (RM), Javed Butler (JB), Ulrich Keller (UK), Johann Ahn (JA), Lars Bullinger (LB), Dominik P. Modest (DPM), Ulf Landmesser (UL), Lorenz Lehmann (LL), Sven Bercker (SB), Ulrich Laufs (ULau), Michael Böhm (MB), Bela Merkely (BM), Monika Diek (MD), Tim Heise (TH), Martin Hellmich (MH), Marius Placzek (MP), Tim Friede (TF), Stefan D. Anker (SDA), Tienush Rassaf (TR)

---

---

**MSK:** fees from Bayer and Novartis.

---

**AAM:** honoraria and/or advisory boards: Amgen, Berlin Chemie, Daiichi Sankyo, Edwards, Novartis, Sanofi. Research funding: Daiichi Sankyo, Edwards, all outside the submitted work. Co-founder of Mycor GmbH, a company focusing on AI-based EKG-algorithms.

---

**MT:** supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; RTG 2989, project number 517043330) and by the German Cancer Aid (Deutsche Krebshilfe); has received honoraria, lecture fees, and grant support from Edwards Lifesciences, AstraZeneca, BMS; Bayer, Novartis, Berlin Chemie, Daiichi-Sankyo, Boehringer Ingelheim, Novo Nordisk, all unrelated to this work.

---

**LB:** honoraria from AbbVie, Amgen, Astellas, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Otsuka, Pfizer, Roche, and Sanofi; research funding from Bayer, Jazz Pharmaceuticals.

---

**UL:** Research support from Abbott, Amgen, Bayer and Novartis.

---

**TH:** institution received research funds from Adocia, Afon Technology, Astra Zeneca, Altimune, Betagenon, Biocon, Bioton, Cass Pharmaceuticals, Civica Foundation, Corteria, Cytoki, Eli Lilly, Enyo Pharma, Gan&Lee Pharmaceuticals, Genova, Nanexa, Neodyne, Novo Nordisk, SamChunDang Pharm. Co., Spiden, Sun Pharma and Zealand Pharma. TH received speaker honoraria from Eli Lilly and Novo Nordisk. TH is a paid consultant to Gan&Lee Pharmaceuticals.

---

**TF:** reports receiving institutional grants from Abbott, the German Research Foundation, the Federal Joint Committee, and the European Commission; receiving personal fees for statistical consultancies including data monitoring committees from Actimed Therapeutics, Bayer, BiosenseWebster, Bristol Myers Squibb, CSL Behring, Daiichi Sankyo, eCover, Enanta Pharmaceuticals, Fresenius Kabi, Galapagos, IQVIA, Novartis, PINK! Aktiv gegen Brustkrebs, PPD, Recardio Inc., Recordati, Relaxera, Roche, Servier, Viatris Inc, VICO Therapeutics and Vifor.

---

**SDA:** reports grants and personal fees from Vifor and Abbott Laboratories, and personal fees for consultancies, trial committee work and/or lectures from Actimed, Alleviant, Astra Zeneca, Bayer, Berlin Heals, Boehringer Ingelheim, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Cytokinetics, Edwards, Impulse Dynamics, Lilly, Mankind Pharma, Medtronic, Novo Nordisk, Occlutech, Pfizer, Regeneron, Relaxera, Repairon, Scirent, Sensible Medical, Vectorious, Vivus, and V-Wave. Named co-inventor of two patent applications regarding MR-proANP (DE 102007010834 & DE 102007022367), but he does not benefit personally from the related issued patents.

---

**JB:** Consultant Abbott, Adaptyx, American Regent, Amgen, AskBio, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CSL Vifor, CVRx, Cytokinetics, Daxor, Diastol, Edwards, Element Sciences, Faraday, Idorsia, Impulse Dynamics, Imbria, Innolife, Intellia, Inventiva, Levator, Lexicon, Eli Lilly, Mankind, Medtronic, Merck, New Amsterdam, Novartis, NovoNordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Reprieve, Roche, Rycarma, Saillent, Salamandra, Salubris, SC Pharma, SQ Innovation, Secretome, Sequanna, Transmural, TekkunLev, Tenex, Tricog, Ultronic, Vera, Zoll.

---

**TR:** honoraria, lecture fees, and grant support from Edwards Lifesciences, AstraZeneca, BMS; Bayer, Novartis, Berlin Chemie, Daiicho-Sankyo, Boehringer Ingelheim, Novo Nordisk, Cardiac Dimensions, and Pfizer, all unrelated to this work. He is co-founder of Bimyo GmbH, a company that develops cardioprotective peptides, co-founder of Mycor GmbH, a company focusing on AI-based EKG-algorithms and co-founder of Yes2NO, developing nitric oxide-based treatments. TR is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; RTG 2989, project number 517043330).

---

All other authors declare no conflict of interest.

---